Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.
Plos One
Prentice, Leah M LM; Miller, Ruth R RR; Knaggs, Jeff J; Mazloomian, Alborz A; Aguirre Hernandez, Rosalia R; Franchini, Patrick P; Parsa, Kourosh K; Tessier-Cloutier, Basile B; Lapuk, Anna A; Huntsman, David D; Schaeffer, David F DF; Sheffield, Brandon S BS
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Annals Of Oncology : Official Journal Of The European Society For Medical Oncology
Loibl, S S; Majewski, I I; Guarneri, V V; Nekljudova, V V; Holmes, E E; Bria, E E; Denkert, C C; Schem, C C; Sotiriou, C C; Loi, S S; Untch, M M; Conte, P P; Bernards, R R; Piccart, M M; von Minckwitz, G G; Baselga, J J
Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.
Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research
Gross, Neil D ND; Bauman, Julie E JE; Gooding, William E WE; Denq, William W; Thomas, Sufi M SM; Wang, Lin L; Chiosea, Simion S; Hood, Brian L BL; Flint, Melanie S MS; Sun, Mai M; Conrads, Thomas P TP; Ferris, Robert L RL; Johnson, Jonas T JT; Kim, Seungwon S; Argiris, Athanassios A; Wirth, Lori L; Nikiforova, Marina N MN; Siegfried, Jill M JM; Grandis, Jennifer R JR
Publication Date: 2014-06-15
Variant appearance in text: PIK3CA: 1598C>T; A533V